Skip to main content
Advertisement
Live broadcast
Main slide
Beginning of the article
Озвучить текст
Select important
On
Off

Specialists from the Gamaleya Center have successfully tested a new Russian Ebola vaccine on live samples of the virus stored in the collections of the Ministry of Defense. To continue their research, scientists need exactly the variant of the pathogen that caused the current outbreak in Africa. However, WHO and the authorities of the Democratic Republic of the Congo have not provided it to the Russian side. At the same time, the Russian Foreign Ministry emphasizes that the country is interested in combating Ebola and is actively cooperating with WHO on this issue. In the absence of effective countermeasures, the number of victims of the disease continues to grow. According to experts, suitable conditions have now developed in the outbreak center for testing all vaccines being developed.

Russian Ebola Vaccine Trials

A new Russian Ebola vaccine being developed to protect against the Bundibugio strain that caused the current outbreak in Africa has been successfully tested on live samples of the virus.

— We have completed the first phase of clinical trials. Preliminary tests were conducted with the 48th Central Research Institute of the Ministry of Defense on live strains of the Ebola virus, which were available. But then from that side (WHO. —Everything has stalled at the stage of transferring the relevant strains that are needed to confirm the vaccine's protectivity", Denis Logunov, director of the Gamaleya National Research Center for Epidemiology and Microbiology, told Izvestia.

врачики
Photo: IZVESTIA/Andrey Erstrem

Initially, the drug was developed to protect against several strains of the virus at once, including Sudan and Bundibugio. However, the creation of such a vaccine turned out to be too expensive and complicated. Since all its components have already been confirmed safe and have passed clinical trials, the developers decided to reduce the composition of the drug to one component — against the Bundibugio strain — and complete the trials on the current pathogen using a simplified procedure.

— We proposed to switch to a single-component vaccine as part of the simplified regulation, since all the necessary tests have already been carried out. Four components are not needed here. It's cheaper and more economically feasible. Our proposal has been made, but there is no response from WHO yet," Denis Logunov said.

The Russian Foreign Ministry told "Izvestia" that the country attaches great importance to international efforts to counter the spread of Ebola caused by the Bundibugio strain, and actively cooperates with the World Health Organization.

"Clinical trials are still underway for the domestic vaccine, although partners from African countries are already showing interest in it," the agency's press service said.

предназначенном для перевозки инфицированных лихорадкой Эбола

Emergency workers in protective suits with insulating breathing apparatus carry a medical module designed to transport Ebola infected people.

Photo: RIA Novosti/Alexander Hrebtov

They recalled that this year, for the first time, a Russian delegation led by Deputy Minister of Health Oleg Salagai took part in a meeting of the WHO Regional Committee for Africa. Among other things, cooperation with the States of the continent in the fight against Ebola was discussed.

In addition, Russian experts joined the WHO Emergency Committee established in connection with the outbreak of infection. At the end of August, the second meeting of the body was held, which confirmed the recommendation to maintain the status of an emergency in the field of public health, which is of international importance.

According to the Ministry of Foreign Affairs, Russia is currently not providing bilateral assistance to the Democratic Republic of the Congo in combating the Ebola outbreak due to the lack of appropriate treatment from the leadership of that country. However, as "Izvestia" was previously informed by the Russian Embassy in the DRC, contacts between the ministries of health of the two countries are continuing.

Эбола
Photo: REUTERS/Gradel Muyisa Mumbere

"Currently, the Russian and Congolese sides are continuing to work on agreeing on a draft memorandum of understanding in the field of healthcare. Issues related to the possible transfer of biological materials, including virus strains, were not considered in the framework of the ongoing contacts, and there were no official requests on this subject from the Congolese side," the embassy said in a response.

Conditions for clinical trials

In the absence of effective means of protection against the Bundibugio strain, the number of cases and deaths in Africa continues to grow. According to the latest data, the number of deaths exceeded 3.5 thousand, and the number of infected — 7.2 thousand.

UN officials said on September 15 that efforts to contain the Ebola epidemic in the eastern Democratic Republic of the Congo were beginning to show results. However, they stressed that the scale of the outbreak is still large and it will take months to stabilize the situation.

— This is still a deadly and large-scale epidemic. There have been some successes, but at the same time, we continue to see an increase in the number of cases in other areas," Julien Harneis, the UN Special Coordinator for the fight against Ebola, said at a briefing in Geneva.

эбола
Photo: RIA Novosti/Ramil Sitdikov

At the moment, there are no specific means of protection against the Bundibugio strain. In addition to Russia, vaccines against it are being developed in other countries. In May, WHO said it would take six to nine months to create such a drug. In August, the American company Moderna announced that the first volunteers in Canada had received the drug as part of clinical trials of a vaccine against the current strain. In July, the University of Oxford began similar tests of its development.

According to Andrey Prodeus, chief pediatric allergist and immunologist at the Ministry of Health of the Moscow Region, suitable conditions have now developed in the epidemic zone for testing the vaccines being developed.

— From my point of view, it is necessary to take all existing variants of Bundibugio vaccines and vaccinate everyone who has not been sick in the outbreak. It will be a pure experiment. There is already enough data on how the disease spread naturally. If it is possible to reduce the number of cases and transmission of infection, this will allow us to evaluate the effectiveness of drugs," he believes.

эбола
Photo: REUTERS/Gradel Muyisa Mumbere

Usually, infectious agents for testing new drugs are transferred to other countries upon official request. According to the expert, the delay in the transmission of the current strain in this case may be due to political reasons. It would probably be easier to finalize the development of the Russian vaccine and test it for the current version of the virus within the framework of bilateral cooperation with the DRC, he believes, since the Congolese side is directly interested in combating the outbreak.

Переведено сервисом «Яндекс Переводчик»

Live broadcast